Bank of New York Mellon
LYEL icon

Bank of New York Mellon’s Lyell Immunopharma LYEL Stock Holding History

Bank of New York Mellon’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$347K Buy
+24,673
New +$447K ﹤0.01% 3934
2025
Q2 		– Sell
-26,289
Closed -$283K – 4212
2025
Q1 		$283K Hold
26,289
– – ﹤0.01% 3730
2024
Q4 		$337K Hold
26,289
– – ﹤0.01% 3716
2024
Q3 		$726K Sell
26,289
-7,309
-22% -$215K ﹤0.01% 3310
2024
Q2 		$974K Buy
33,598
+1,924
+6% +$91.6K ﹤0.01% 3220
2024
Q1 		$1.41M Sell
31,674
-1,377
-4% -$59K ﹤0.01% 2959
2023
Q4 		$1.28M Sell
33,051
-27
-0.1% -$972 ﹤0.01% 3063
2023
Q3 		$972K Buy
33,078
+118
+0.4% +$5.6K ﹤0.01% 3167
2023
Q2 		$2.1M Buy
32,960
+263
+0.8% +$14.6K ﹤0.01% 2803
2023
Q1 		$1.54M Sell
32,697
-114
-0.3% -$6.1K ﹤0.01% 2941
2022
Q4 		$2.28M Sell
32,811
-127
-0.4% -$12.6K ﹤0.01% 2790
2022
Q3 		$4.83M Buy
32,938
+5,475
+20% +$741K ﹤0.01% 2312
2022
Q2 		$3.58M Buy
27,463
+7,955
+41% +$813K ﹤0.01% 2496
2022
Q1 		$1.97M Buy
19,508
+15,944
+447% +$1.93M ﹤0.01% 2951
2021
Q4 		$552K Buy
3,564
+633
+22% +$141K ﹤0.01% 3741
2021
Q3 		$867K Buy
+2,931
New +$878K ﹤0.01% 3471

Other funds holding LYEL

OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Bank of New York Mellon's LYEL Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in Lyell Immunopharma (LYEL) in Q2 2026: 24,673 shares worth $347K. The stake represents ﹤0.01% of the portfolio and ranks #3934 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in LYEL as recently as Q1 2025.

Bank of New York Mellon first reported a position in LYEL in Q3 2021 and has held it in 16 quarters since. The position peaked at $4.83M in Q3 2022. 29 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Bank of New York Mellon held 24,673 shares of Lyell Immunopharma worth $347K as of Q2 2026.
  • Lyell Immunopharma was a new Bank of New York Mellon position in Q2 2026.
  • Lyell Immunopharma made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3934 holding.
  • Bank of New York Mellon first reported a position in Lyell Immunopharma in Q3 2021 and has held it in 16 quarters since.
  • Bank of New York Mellon's Lyell Immunopharma position peaked at $4.83M in Q3 2022.
  • 29 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.